Letter to the Editor
Impacting Global Health Delivery Through Advocacy: The Case of Losartan
Authors:
David J. Heller ,
Arnhold Institute for Global Health, Icahn School of Medicine at Mount Sinai, New York, NY, US
Sandeep P. Kishore
Arnhold Institute for Global Health, Icahn School of Medicine at Mount Sinai, New York, NY, US
Abstract
Highlights
- The WHO’s EML improves medicine access.
- Anyone can lobby to add a medicine to the EML, so we added losartan in 2017.
- Evidence now shows losartan is more impactful than previously realized.
- You too can use the EML to effect policy change—by adding to or amending it.
- Also, you can hold governments accountable to keep EML medicines on their shelves.
Published on
01 Mar 2019.
Downloads
